Willem Lybaert

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Cancer and renal insufficiency results of the BIRMA study

Nicolas Janus, Vincent Launay‐Vacher, E. Byloos et al. · British Journal of Cancer · 2010 · 190 citations · Full text

<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer et al. · Clinical Cancer Research · 2018 · 161 citations · Full text

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington et al. · Genome Medicine · 2018 · 128 citations · Full text

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer

Christian Rolfo, Paolo Manca, Roberto Salgado et al. · ESMO Open · 2018 · 105 citations · Full text